Next Article in Journal
Personomics: The Missing Link in the Evolution from Precision Medicine to Personalized Medicine
Next Article in Special Issue
Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors
Previous Article in Journal
Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics

Personalized Nanomedicine: A Revolution at the Nanoscale

Sagetis Biotech, 08017 Barcelona, Spain
Department of Pharmacy and Pharmaceutic Technology and Physicochemistry, R + D Associated Unit to CSIC, Faculty of Pharmacy and Food Sciences and Institute of Nanosciences and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08028 Barcelona, Spain
Authors to whom correspondence should be addressed.
Academic Editor: Stephen B. Liggett
J. Pers. Med. 2017, 7(4), 12;
Received: 31 August 2017 / Revised: 4 October 2017 / Accepted: 4 October 2017 / Published: 12 October 2017
(This article belongs to the Special Issue Personalized Nanomedicine)
Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to a cohort of patients. In the present review, the properties and requirements of pharmaceutical dosage forms at the nanoscale, so-called nanomedicines, are been highlighted. An overview of the main current nanomedicines in pre-clinical and clinical development is presented, detailing the challenges to the personalization of these therapies. Next, the process of development of novel nanomedicines is described, from their design in research labs to their arrival on the market, including considerations for the design of nanomedicines adapted to the requirements of the market to achieve safe, effective, and quality products. Finally, attention is given to the point of view of the pharmaceutical industry, including regulation issues applied to the specific case of personalized medicine. The authors expect this review to be a useful overview of the current state of the art of nanomedicine research and industrial production, and the future opportunities of personalized medicine in the upcoming years. The authors encourage the development and marketing of novel personalized nanomedicines. View Full-Text
Keywords: personalized nanomedicine; nanotherapeutics; nanodrugs; nanosystems; scale-up; nanomedicines market; stakeholders personalized nanomedicine; nanotherapeutics; nanodrugs; nanosystems; scale-up; nanomedicines market; stakeholders
Show Figures

Figure 1

MDPI and ACS Style

Fornaguera, C.; García-Celma, M.J. Personalized Nanomedicine: A Revolution at the Nanoscale. J. Pers. Med. 2017, 7, 12.

AMA Style

Fornaguera C, García-Celma MJ. Personalized Nanomedicine: A Revolution at the Nanoscale. Journal of Personalized Medicine. 2017; 7(4):12.

Chicago/Turabian Style

Fornaguera, Cristina, and Maria J. García-Celma 2017. "Personalized Nanomedicine: A Revolution at the Nanoscale" Journal of Personalized Medicine 7, no. 4: 12.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop